Limosilactobacillus vaginalis BC17
Limosilactobacillus vaginalis BC17 is a lactic acid bacterium originally isolated from the vaginal microbiota and studied for potential probiotic applications. In vitro research has characterized its functional profile, metabolic properties for potential use in functional foods, and postbiotic activity, including bifidogenic effects, documented in laboratory settings. Studies have also examined formulation development including fast-disintegrating oral tablets. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 3 body-system-tagged papers that concern each system. Research coverage, not measured effect.
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 1 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
3 papers reference this strain in the probiotic database.
Discussion
Be the first to comment.
Sign in to join the discussion.
Citations
Selected papers that name this strain.
-
[1]
PMID 40871031 →Functional and Safety Profile of Limosilactobacillus vaginalis and Development of Oral Fast-Disintegrating Tablets for Gut Microbiota Modulation· Pharmaceutics · 2025